Hoechst 33258 selectively inhibits group I intron self-splicing by affecting RNA folding.
Fungal pathogens are increasing in prevalence due to an increase in resistant strains and the number of immunocompromised humans. Candida albicans is one of these pathogens, and approximately 40% of strains contain a group I self-splicing intron, which is a potential RNA drug target, in their large subunit rRNA precursor. Here, we report that Hoechst 33258 and derivatives thereof are selective inhibitors of C. albicans group I intron self-splicing with an IC50 of 17 microM in 2 mM Mg2+. Chemical probing of the intron in the presence of Hoechst 33258 reveals that the folding of several nucleotides in the P4/P6 region of the intron is affected. A nucleotide near the J4/5 region is protected from chemical modification in the presence of Hoechst 33258 and several nearby are more reactive; this suggests that this region is the molecule's binding site. These results expand the available information on small-molecule targeting of RNA and suggest that the RNA-targeting scaffold provided by Hoechst may prove valuable in designing compounds that inhibit the functions of RNA.
Disney
Matthew D
MD
Department of Chemistry, University of Rochester, Rochester, NY 14627-0216, USA.
Childs
Jessica L
JL
Turner
Douglas H
DH
D001483:Base Sequence; D006690:Bisbenzimidazole / Q000494:pharmacology*; D002176:Candida albicans / Q000235:genetics*; D020134:Catalytic Domain / Q000235:genetics; D020128:Inhibitory Concentration 50; D007438:Introns / Q000235:genetics*; D008969:Molecular Sequence Data; D009690:Nucleic Acid Conformation; D012326:RNA Splicing / Q000187:drug effects* / Q000235:genetics; D044563:RNA, Ribosomal, Self-Splicing / Q000037:antagonists & inhibitors* / Q000235:genetics
D044563:RNA, Ribosomal, Self-Splicing; D006690:Bisbenzimidazole